Device Accuracy of Non-invasive Glucose Measurements in Ethnic Skin

Diabetes Mellitus Clinical Trial

Official title:

Device Accuracy of Non-invasive Glucose Measurements in Ethnic Skin

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT04060693
• Other study ID #: RSP 18
• Status: Withdrawn
• Phase: N/A
• Start date: December 10, 2019
• Est. completion date: December 10, 2019

Study information

• Verified date: November 2023
• Source: RSP Systems A/S
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This clinical study has been launched to collect spectral raman data paired with validated glucose reference values in private homes of subjects.

Description:

The subjects enrolled in this protocol will dedicate 30 days of home-based measurement, scheduled within a 40 days' time frame. For reference measurements, subjects will be equipped with a blood glucose meter (Contour Next One, Ascenia). Optical measurements are collected with the investigational medical device. Each day of measurements consists of four sessions each comprising two capillary blood glucose measurement with a blood glucose meter and two investigational medical device measurements.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: December 10, 2019
• Est. primary completion date: December 10, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Between 18 and 40 years of age.

• Have a diagnosis of diabetes mellitus.

• Distribution of skin phototype: 50-70 % of enrolled subjects phototype IV, 20-40 % of enrolled subjects phototype III, 5-15 % of enrolled subjects phototype II, 5-15 % of enrolled subjects phototype I.

• Be willing to perform a minimum of 8 finger sticks per day during the study.

• Be willing to perform a minimum of 8 optical measurements per day during the study.

• Be willing to provide written signed and dated informed consent.

Exclusion Criteria:

• Breastfeeding, pregnant, attempting to conceive or not willing and able to practice birth control during the study execution (applicable to female subjects only).

• Subjects not able to understand and read English.

• Inability to comply with the study procedures as described by the study protocol, according to the opinion of the investigator.

• Subject is not able to hold hand/arm steadily (including tremors and Parkinson's Disease).

• Diagnosed with cardiovascular diseases.

• Reduced circulation in right hand evaluated by Allen's test.

• Subjects receiving anticoagulants, active cancer treatment, tetracyclines and other medication/topical agents increasing photosensitivity.

• Radiotherapy for the past six months.

• Extensive skin changes, tattoos or diseases on probe application site (thenar) that could interfere with the accuracy of the interstitial glucose measurements.

• Known allergy to medical grade alcohol used to clean the skin.

• Systemic or topical administration of glucocorticoids for the past 7 days and under investigation.

• Subjects undergoing dialysis treatment.

• Concomitant medical condition which could present a risk to the safety or welfare of the subject or study staff.

• Medical history or any condition that may, in the opinion of the investigator, compromise subject's ability to participate.

• Subjects currently enrolled in another study.

Related Conditions & MeSH terms

• Diabetes Mellitus

Intervention

Device:
• P0.5
Investigational Medical Device collecting spectral raman data from tissue.

Locations

Country	Name	City	State
United Kingdom	Centre for Rare Disease ITM, Heritage Building (Queen Elizabeth Hospital Birmingham)	Birmingham	Edgbaston

Sponsors (1)

Lead Sponsor	Collaborator
RSP Systems A/S

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Measurement accuracy of IMD	Accuracy of measurements performed on the IMD will be evaluated by data from subjects. Data will be analyzed by Mean Absolute Relative Difference (MARD).	8 months
Secondary	Safety evaluation: paucity of adverse events	Safety of the IMD will be evaluated in a descriptive manner by the paucity of adverse events reported during the clinical study.	8 months